Loading
Latest filing published 22 May 2013 for Medite Cancer Diagnostics, Inc., €2.5M.
No signal scores available.
Based on 72 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Robert F. Mccullogh Jr. appears in our data through filings on Medite Cancer Diagnostics, Inc. shares, published by SEC (Form 4). In total, 82 filings cover trades dated from 3 April 2007 to 20 May 2013.
On the market, this insider has only ever bought: 74 purchases, €606k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 6 share grants and 2 option exercises.
In size, the median ticket on the buying side is €3,393. Looking at 72 purchases old enough to measure, the stock rose over the following 90 days in 3% of cases; the median change was -22.2%. They describe history only and say nothing certain about the share price ahead.
The latest filing, published on 22 May 2013, reports a share grant of €2.5M in Medite Cancer Diagnostics, Inc. The last insider purchase was made public on 28 June 2012, 5,231 days ago. Typically, a trade is published a median of 10 days after it takes place. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 80 declarations